IDBS and Scitara to Integrate the Scitara Digital Lab Exchange and IDBS Biopharmaceutical Lifecycle Management Platforms

[Source]

IDBS, a leading innovator in Biopharmaceutical Lifecycle Management (BPLM), and Scitara, a pioneer in laboratory IoT, have entered into a strategic partnership to create a combined solution that will significantly extend IDBS Polar BPLM’s laboratory data connectivity and instrument integration capabilities. This integrated solution augments the Polar workflow capabilities by addressing the challenge of sharing and digitalizing laboratory data across the biopharmaceutical lifecycle, while ensuring data integrity and supporting insight.

Out-of-the-box Polar workflows powered by Scitara DLX will remove risky and inefficient manual processes and deliver high-quality contextualized data that supports decision-making and insights throughout the biopharmaceutical lifecycle. The combined solution will provide out-of-the-box integration with instruments, equipment, informatics systems and enterprise platforms, significantly reducing the time and complexity of Polar implementations.

“Universal access to laboratory data is crucial to the success of science-based industry’s digital transformation journey,” noted Ajit Nagral, CEO of Scitara. “The Scitara Digital Laboratory Exchange (DLX) platform provides seamless peer-to-peer data connectivity for all laboratory instruments and applications, enables simple yet comprehensive data transformation and workflow automation, and creates a trusted digital trail of all lab data transactions for further analysis and decision-making. Our partnership with IDBS will enable their BPLM solution to interoperate with hundreds of systems connected to our laboratory data exchange backbone. We are excited to bring these capabilities to the IDBS user community and look forward to regulated and non-regulated customers reaping the benefits of our joint solution.

“Seamless integration of workflows, equipment and data across the biopharmaceutical lifecycle is one of the fundamental challenges in reducing the time and cost of developing novel biological therapies and vaccines,” said Pietro Forgione, Vice President, Strategy at IDBS.

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!

  • <<
  • >>

Join the Discussion